Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1)

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2095-2102

  Wallace, Aaron ^a   West, Kim ^a,b   Rothman, Alan ^b   Ennis, Francis A ^b   Lu, Shan ^a   Wang, Shixia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Antibody; Cell mediated immune responses; DNA vaccine; Gag; HIV 1

Indexed keywords

DNA VACCINE; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID VECTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EXPERIMENTAL MOUSE; EXPRESSION VECTOR; FEMALE; GENE GUN IMMUNIZATION; GROUP SPECIFIC ANTIGEN GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; IN VITRO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TRANSPORT; STAINING; VIRUS GENE; VIRUS STRAIN; WILD TYPE; ZINC FINGER MOTIF;

ANTIBODY; CELL MEDIATED IMMUNE RESPONSES; DNA VACCINE; GAG; HIV-1;

ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PROTEIN TRANSPORT; T-LYMPHOCYTES; VACCINES, DNA;

EID: 84885094087     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26009     Document Type: Article

References (61)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, De Souza M, Adams E, et al.; MOPH-TAVEG Investigators. Vaccination with AIVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20; PMID: 19843557; http://dx.doi.org/10. 1056/NEJMoa0908492
2. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012;366:1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoal 113425
3. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-9; PMID: 11797012; http://dx.doi.org/10.1038/415335a
4. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004;10:806-10; PMID: 15286782; http://dx.doi.org/10.1038/nm0804-806
5. Barouch DH, Liu J, Peter L, Abbink P, Iampietro MJ, Cheung A, Alter G, Chung A, Dugast AS, Frahm N, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 2013;207:248-56; PMID:23125443; http://dx.doi.org/10.1093/infdis/jis671
6. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-32; PMID: 15247437; http://dx.doi.org/10.1126/science.1098632
7. Bray M, Prasad S, Dubay JW, Hunter E, Jeang KT, Rekosh D, Hammarskjold ML. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A 1994;91:1256-60; PMID:8108397; http://dx.doi.org/10.1073/ pnas.91.4.1256
8. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-5; PMID:8207839
9. Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, Borrow P, Saag MS, Shaw GM, Sekaly RP, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994;370:463-7; PMID:8047166; http://dx.doi.org/10.1038/370463a0
10. Robinson HL, Sharma S, Zhao J, Kannanganat S, Lai L, Chennareddi L, Yu T, Montefiori DC, Amara RR, Wyatt LS, et al. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses 2007;23:1555-62; PMID:18160013; http://dx.doi.org/10.1089/aid.2007.0165
11. Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001;410:1002-7; PMID:11309631;0http://dx.doi.org/10.1038/ 35073500
12. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-74; PMID:9345075; http://dx.doi.org/10.1056/NEJM199710303371803
13. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997;185:293-303; PMID:9016878; http://dx.doi.org/10.1084/jem.185.2.293
14. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74; PMID: 11393868; http://dx.doi.org/10.1126/science.105 8915
15. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5; PMID:11797011; http://dx.doi.org/10.1038/415331a
16. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokineaugmented DNA vaccination. Science 2000;290:486-92; PMID: 11039923; http://dx.doi.org/10.1126/science.290.5491.486
17. Dou J, Wang JJ, Chen X, Li H, Ding L, Spearman P. Characterization of a myristoylated, monomeric HIV Gag protein. Virology 2009;387:341-52; PMID:19285328; http://dx.doi.org/10.1016/j. virol.2009.02.037
18. McAdam S, Kaleebu P, Krausa P, Goulder P, French N, Collin B, Blanchard T, Whitworth J, McMichael A, Gotch F. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 1998;12:571-9; PMID:9583596; http://dx.doi.org/10.1097/00002030-199806000-00005
19. Kulkarni V, Rosati M, Valentin A, Ganneru B, Singh AK, Yan J, Rolland M, Alicea C, Beach RK, Zhang GM, et al. HIV-1 p24 (gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One 2013;8:e60245; PMID:23555935; http://dx.doi.org/10.1371/journal.pone.0060245
20. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, et al. A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. Immunity 2013;38:425-36; PMID:23521884; http://dx.doi. Org/10.1016/j.immuni.2012.11.021
21. Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu SL, Villinger F, Else JG, Novembre FJ, Yoon JK, et al. Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One 2011;6:e22010; PMID:21799765; http://dx.doi.org/10.1371/ journal. pone.0022010
22. Manuel ER, Yeh WW, Seaman MS, Furr K, Lifton MA, Hulot SL, Autissier P, Letvin NL. Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus. J Virol 2009;83:10028-35; PMID:19641002; http://dx.doi.org/10.1128/JVI. 01015-09
23. Hammonds J, Chen X, Zhang X, Lee F, Spearman P Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 2007;25:8036-48; PMID: 17936444; http://dx.doi.org/10.1016/j. vaccine.2007.09.016
24. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, et al.; VRC 009 Study Team; VRC 010 Study Team. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5:e9015; PMID:20126394; http://dx.doi.org/10.1371/journal.pone.0009015
25. Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzeederived recombinant adenoviral vector immunization. J Immunol 2013;190:2720-35; PMID:23390298; http://dx.doi.org/10.4049/j immunol. 1202861
26. Acierno PM, Schmitz JE, Gorgone DA, Sun Y, Santra S, Seaman MS, Newberg MH, Mascola JR, Nabel GJ, Panicali D, et al. Preservation of functional virusspecific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J Immunol 2006;176:5338-45; PMID: 16622001
27. Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006;346:151-68; PMID:16325880; http://dx.doi.org/10.1016/j.virol.2 005.10.038
28. Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006;348:341-53; PMID: 16460776; http://dx.doi.org/ 10.1016/j, virol.2005.12.029
29. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26:3947-57; PMID: 18724414; http://dx.doi.org/10.1016/j.vaccine.2007.12.060
30. Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, Chennareddi L, et al. DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses 2004;20:335-47; PMID: 15650426; http://dx.doi.org/10.1089/aid.2004.20.1335
31. Morellet N, Demene H, Teilleux V, Huynh-Dinh T, De Rocquigny H, Fournie-Zaluski MC, Roques BP. Structure of the complex between the HIV-1 nucleocapsid protein NCp7 and the single-stranded pentanucleotide d (ACGCC). J Mol Biol 1998;283:419-34; PMID:9769215; http://dx.doi.org/10.1006/jmbi.1998.2098
32. Poon DT, Wu J, Aldovini A. Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity. J Virol 1996;70:6607-16; PMID:8794295
33. Freed EO. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 1998;251:1-15; PMID: 9813197; http://dx.doi.org/10.1006/viro.1998.9398
34. Chow JY, Jeffries CM, Kwan AH, Guss JM, Trewhella J. Calmodulin disrupts the structure of the HIV-1 MA protein. J Mol Biol 2010;400:702-14; PMID:20488189; http://dx.doi.org/10.10l6/j.jmb.2010.05.022
35. Wellensiek BP, Sundaravaradan V, Ramakrishnan R, Ahmad N. Molecular characterization of the HIV-1 gag nucleocapsid gene associated with vertical transmission. Retrovirology 2006;3:21; PMID: 16600029; http://dx.doi.org/10. 1186/1742-4690-3-21
36. Baba S, Takahashi K, Koyanagi Y, Yamamoto N, Takaku H, Gorelick RJ, Kawai G. Role of the zinc fingers of HIV-1 nucleocapsid protein in maturation of genomic RNA. J Biochem 2003;134:637-9; PMID: 14688228; http://dx.doi.org/10. 1093/jb/mvg200
37. Aduri R, Briggs KT, Gorelick RJ, Marino JP. Molecular determinants of HIV-1 NCp7 chaperone activity in maturation of the HIV-1 dimerization initiation site. Nucleic Acids Res 2013;41:2565-80; PMID:23275531; http://dx.doi.org/10. 1093/nar/gksl350
38. Ramboarina S, Druillennec S, Morellet N, Bouaziz S, Roques BP. Target specificity of human immunodeficiency virus type 1 NCp7 requires an intact conformation of its CCHC N-terminal zinc finger. J Virol 2004;78:6682-7; PMID:15163759; http://dx.doi.org/10.1128/JVI.78.12.6682-6687.2004
39. Mark-Danieli M, Laham N, Kenan-Eichler M, Castiel A, Melamed D, Landau M, Bouvier NM, Evans MJ, Bacharach E. Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity. J Virol 2005;79:7756-67; PMID:15919928; http://dx.doi.org/10.1128/JVI.79.12.7756-7767. 2005
40. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:938-41; PMID: 1470917; http://dx.doi.org/10.1126/science. 1470917
41. Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, Unger RE, Ramos RA, Kiyono H, McGhee JR, et al. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol 1992;21:99-107; PMID: 1433273
42. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-5; PMID:7892606; http://dx.doi.org/10.1126/ science.7892606
43. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999;5:194-203; PMID:9930868; http://dx.doi.org/10.1038/8859
44. Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995;209:147-54; PMID:7747464; http://dx.doi.org/10. 1006/viro.1995.1238
45. Ulmer JB, Wahren B, Liu MA. DNA vaccines: recent technological and clinical advances. Discov Med 2006;6:109-12; PMID:17234l44
46. Wang S, Goguen JD, Li F, Lu S. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine 2011;29:6802-9; PMID:21199697; http://dx.doi.org/10.1016/j. vaccine.2010.12.062
47. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006;24:4531-40; PMID: 16140431; http://dx.doi.org/10.1016/j.vaccine.2005.08.023
48. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, Zhou A, Li J, Cao WC, Huang Z, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 2011;6:e28757; PMID:22205966; http://dx.doi.org/10. 1371/journal.pone.0028757
49. Berthoux L, Pechoux C, Ottmann M, Morel G, Darlix JL. Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J Virol 1997;71:6973-81; PMID:9261426
50. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, Kalish ML, Shaw GM, Allen S, Hahn BH, et al.; UNAIDS and NIAID Networks for HIV Isolation and Characterization. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses 2001;17:161-8; PMID:11177395; http://dx.doi.org/10.1089/0889222015 0217247
51. Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J Virol 2000;74:5997-6005; PMID: 10846081; http://dx.doi.org/10.1128/ JVI.74.13.5997-6005.2000
52. Aldovini A, Young RA. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol 1990;64:1920-6; PMID:2109098
53. Urbaneja MA, Kane BP, Johnson DG, Gorelick RJ, Henderson LE, Casas-Finet JR. Binding properties of the human immunodeficiency virus type 1 nucleocapsid protein p7 to a model RNA: elucidation of the structural determinants for function. J Mol Biol 1999;287:59-75; PMID: 10074407; http://dx.doi.org/10.1006/ jmbi.1998.2521
54. Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, Weng J, Montefiori DC, Sodroski J, Robinson HL. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the VI/2 and V3 regions. AIDS Res Hum Retroviruses 1998;14:151-5; PMID:9462925; http://dx.doi.org/10.1089/aid.1998.14.151
55. Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. Methods Mol Med 2000;29:355-74; PMID:21374335
56. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90:8392-6; PMID:7690960; http://dx.doi.org/10.1073/pnas.90.18.8392
57. Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE Jr., Marovich M, Spearman P. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J Virol 2005;79:5537-47; PMID: 15827168; http://dx.doi.org/10.1128/JVI.79.9.55 37-5 547.2005
58. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006;350:34-47; PMID: 16616287; http://dx.doi.org/10.1016/j.virol.2006.02.032
59. Shen M, Wang S, Ge G, Xing Y, Ma X, Huang Z, Lu S. Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen. Vaccine 2010;28:7288-96; PMID:20831917; http://dx.doi.org/10. 1016/j.vaccine.2010.08.081
60. Xing Y, Huang Z, Lin Y, Li J, Chou TH, Lu S, Wang S. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen. Vaccine 2008;26:5145-52; PMID: 18462847; http://dx.doi.org/10.1016/j. vaccine.2008.03.072
61. Mata M, Travers PJ, Liu Q, Frankel FR, Paterson Y. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 1998;161:2985-93; PMID: 9743362